LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Drummond, M (2006)
Publisher: BMJ Group
Languages: English
Types: Article
Subjects: Report
The financial constraints faced by most health systems today make it necessary for manufacturers of new, expensive drugs to demonstrate value for money. This paper describes the different types of economic evaluation; the increasing use of these analysis in decision making; their application to new drugs in the field of in rheumatoid arthritis; and the pros and cons of pharmacoeconomics studies from the perspective of the patients, the physicians, and the general population.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1 Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes, 3rd edn., Oxford: Oxford University Press, 2005.
    • 2 Commonwealth of Australia. Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee: including Economic Analyses. Canberra: Department of Health and Community Services, 1995.
    • 3 Cairns J. Providing guidance to the NHS: the Scottish Medicines Consortium and the National Institute for Clinical Excellence compared. Health Policy 2006;76:134-43.
    • 4 Academy of Managed Care Pharmacy. The AMCP Format for Formulary Submissions. Version 2.1. Alexandria VA: AMCP, April, 2005.
    • 5 Drummond MF. Economic evaluation in health care: is it really useful or are we just kidding ourselves? Aust Econ Rev 2004;37:183-97.
    • 6 Hjelmgren J, Berggren F, Andersson F. Health economic guidelinessimilarities, differences and some implications. Value Health 2001;4:225-50.
    • 7 National Institute for Health and Clinical Excellence. Guide to the Methods of Technology Appraisal. London: NICE, 2004.
    • 8 Maetzel A, Tugwell P, Boers M, Guillemin F, Coyle D, Drummond M, et al. Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case. J Rheumatol 2003;30:891-6.
    • 9 Anis AH, Gagnon Y. Using economic evaluations to make formulary coverage decisions: so much for guidelines. Pharmacoeconomics 2000;18:55-62.
    • 10 Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ 2004;329:224-7.
    • 11 Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004;13:437-52.
    • 12 George B, Harris A, Mitchell A. Cost-effectiveness analysis and the consistency of decision-making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics 2001;19:1103-9.
    • 13 Kobelt G, Jo¬®nsson L, Young A, Eberhardt K. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology 2003;42:326-35.
    • 14 Bansback N, Brennan A, Ghatnekar O. The cost-effectiveness of adalimumab in the treatment of moderate to severe rheumatoid arthritis patients in Sweden. Ann Rheum Dis 2005;64:995-1002.
    • 15 Drummond MF, Barbieri M, Wong JB. Analytic choices in economic models of treatments for rheumatoid arthritis: what makes a difference? Med Decis Making 2005;25:520-33.
    • 16 Kobelt G, Andlin-Sobocki P, Brophy S, Jonsson L, Calin A, Braun J. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade). Rheumatology 2004;43:1158-66.
    • 17 National Institute for Health and Clinical Excellence. Osteoarthritis and Rheumatoid Arthritis-coxII Inhibitors, Technology Appraisal No.27. London: NICE, July, 2001.
    • 18 Garrison L, Towse A. The drug budget silo mentality in Europe: an overview. Value Health 2003;6(suppl 1):S1-9.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article